What is Moderna's expected EPS for Q2 2026?

Analysts expect Moderna (MRNA) to report consensus EPS of approximately $-2.06 for Q2 2026. Estimates range from $-2.35 to $-1.80.

What revenue do analysts expect for Moderna in Q2 2026?

The consensus revenue forecast for Moderna (MRNA) in Q2 2026 is approximately $103M. Forecasts range from $75M to $155M.

How many analysts cover Moderna?

11 analysts contribute to the Moderna (MRNA) Q2 2026 consensus estimate.

Has Moderna beaten earnings estimates recently?

Moderna beat analyst EPS estimates in 1 of the last 1 quarter. Moderna beat revenue estimates in 1 of 1. In the most recent quarter (Q1 2026), Moderna EPS beat by 23.5% and revenue beat by 64.6%.

When does Moderna report Q2 2026 earnings?

Moderna (MRNA) is expected to report Q2 2026 earnings on July 31, 2026 before market open.

MRNA Q2 2026 earnings estimate

Consensus EPS · Q2 2026

-$2.06

Consensus revenue · Q2 2026

$103.1M

Analysts

Expected report

Jul 31, 2026

Before open

Upcoming earnings

Locks in 7 days 11 hours · BMO: Locks 8:00 PM ET previous day

Revenue$103.1M$75M – $155M

EPS-$2.06-$2.35 – -$1.80

What to watch

Analyst ratings: Mixed

Make your prediction

Analyst consensus

Based on estimates from 11 analysts.

Metric	Low	Consensus	High
Revenue	$75M	$103.1M	$155M
EPS	-$2.35	-$2.06	-$1.80
EBITDA	-$38.7M	-$24.5M	-$14.5M
EBIT	-$42.7M	-$27M	-$16M
Net income	-$959.1M	-$804M	-$538.7M

Revenue$103.1M
EPS-$2.06
EBITDA-$24.5M
EBIT-$27M
Net income-$804M

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q1 2026	$389M	$236.4M	+64.6%	-$3.40	-$4.45	+23.5%

Q1 2026+64.6%+23.5%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Grade A — Strong upward revisions

Metric	Now	30d ago	60d ago	90d ago	30d Δ
Revenue	$103.1M	$101.8M	—	—	+1.3%
EPS	-$2.04	-$2.06	—	—	+1.2%

2 revised up (30d)0 revised down (30d)

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for Moderna (MRNA) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 5 analysts.

Low: $25.00
Consensus: $46.11
Median: $45.00
High: $77.00
Current: $58.07
Upside: -20.6%

Upside calculated vs most recent trading price of $58.07.

Analyst ratings

Consensus: Hold — based on 27 analyst ratings.

Buy 7Hold 16Sell 4

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Jul 21, 2026	Goldman Sachs	maintain	Neutral	Neutral
Jul 8, 2026	Morgan Stanley	maintain	Equal Weight	Equal Weight
Jul 7, 2026	RBC Capital	maintain	Sector Perform	Sector Perform
Jul 7, 2026	B of A Securities	maintain	Underperform	Underperform
Jun 26, 2026	Piper Sandler	maintain	Overweight	Overweight
Jun 8, 2026	B of A Securities	maintain	Underperform	Underperform
May 4, 2026	UBS	maintain	Neutral	Neutral
May 4, 2026	RBC Capital	maintain	Sector Perform	Sector Perform
May 4, 2026	Goldman Sachs	maintain	Neutral	Neutral
May 4, 2026	Evercore ISI Group	maintain	In Line	In Line

Jul 21, 2026Goldman SachsNeutral
Jul 8, 2026Morgan StanleyEqual Weight
Jul 7, 2026RBC CapitalSector Perform
Jul 7, 2026B of A SecuritiesUnderperform
Jun 26, 2026Piper SandlerOverweight
Jun 8, 2026B of A SecuritiesUnderperform
May 4, 2026UBSNeutral
May 4, 2026RBC CapitalSector Perform
May 4, 2026Goldman SachsNeutral
May 4, 2026Evercore ISI GroupIn Line

Frequently asked questions

Moderna (MRNA) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

MRNA Overview

Counters

Income Statement

Cash Flow

Capital Return

Buybacks

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation